Overview
In this matter, Optieum Biotechnologies Inc., a drug discovery biotech venture advancing research and development of CAR-T cell therapies using its proprietary Eumbody System technology, raised JPY 1.33 billion through a third-party allotment of shares to existing and new investors, with Saisei Ventures as lead investor.
LegalAgent served as legal advisor to Optieum Biotechnologies Inc., including analyzing legal issues relating to the Series A round fundraising, reviewing investment-related agreements, corporate approval documents and other materials, and supporting the process toward the execution of the fundraising.